Inhibition of proliferation, invasion and adhesion of liver cancer cells by 5-azacytidine and butyrate

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 2901-2906

  Wang, Xiao Min ^b   Li, Jing ^a   Evers, B Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE

Author keywords

5 Azacytidine; Butyrate; Cell cycle; Cyclin dependent kinase inhibitors

Indexed keywords

AZACITIDINE; BUTYRIC ACID; PROTEIN P21; PROTEIN P27; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AZACITIDINE; BUTYRIC ACID; CELL ADHESION; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; HUMANS; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0033404082     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
2. Tsai S-L and Liaw Y-F: Etiology and pathogenesis of hepatocellular carcinoma. Dig Surg 12: 7-15, 1995.
3. Parkin DM, Piani P and Ferlay J: Estimates of the world wild wide incidence of 18 major cancers. Int J Cancer 54: 494-622, 1993.
4. Sherman M: Hepatocellular carcinoma. Gastroenterologist 3: 55-66, 1995.
5. Carr BI, Flickinger JC and Lotze MT: Cancer of the liver. In: Cancer - principles & practice of oncology (DeVita VT Jr, Hellman S, Rosenberg SA, eds). New York, Lippincott-Raven 1997, pp 1087-1114.
6. Nerenstone SR, Ihde DC and Friedman MA: Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15: 1-31, 1988.
7. Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eight GHA Clowes Memorial Award Lecture. Cancer Res 50: 6130-6138, 1990.
8. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 79: 547-550, 1994.
9. Pardee AB: G1 events and regulation of cell proliferation. Science 246: 603-608, 1989.
10. Nigg EA: Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17: 471-480, 1995.
11. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
12. Elledge SJ and Harper JW: Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852, 1994.
13. Macleod KF, Sherry N, Hannon G, et al: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-944, 1995.
14. Yoshida K, Murohashi I and Hiroshima K: p53-independent induction of p21 (WAF1/CIP1 ) during differentiation of HL-60 cells by tumor necrosis factor alpha. Int J Hematol 65: 41-48, 1996.
15. Traganos F, Seiter K, Feldman E, Halicka HD and Darzynkiewicz Z: Induction of apoptosis by camptothecin and topotecan. Ann NY Acad Sci 803: 101-110, 1996.
16. Litvak DA, Evers BM, Hwang KO, Hellmich MR, Ko TC and Townsend CM Jr: Butyrate-induced differentiation of Caco-2 cells is associated with apoptosis and early induction of p21waf1/cip1 and p27kip1. Surgery 124: 161-170, 1998.
17. Taylor SM and Jones PA: Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 17: 771-779, 1979.
18. Creusot F, Acs G, and Christman JK: Inhibition of DNA methyltransferases and induction of Friend crythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257: 2041-2048, 1982.
19. Jones PA and Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93, 1980.
20. Pinto A and Zagonel V: 5-aza-2′deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 7: 51-60, 1993.
21. Kantarjian HM, Estey EH and Keating MA: New chemotherapeutic agents in acute myeloid leukemia. Leukemia 10: 4-6, 1996.
22. Kritz AD, Raptis G and Menendez-Botet C: Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. Am J Hematol 51: 117-121, 1996.
23. Zoref-Shani E, Lavie R, Bromberg Y, et al: Effects of differentiation-inducing agents on purine nucleotide metabolism in an ovarian cancer cell line. J Cancer Res Clin Oncol 120: 717-722, 1994.
24. Rivero JA and Adunyah SE: Sodium butyrate induces tyrosine phosphorylation and activation of MAP kinase (ERK-1) in human K562 cells. Biochem Biophys Res Com 224: 796-801, 1996.
25. Schroy PC, Rustgi AK, Ikonomu E, et al: Growth and intestinal differentiation are independently regulated in HT29 colon cancer cells. J Cell Physiol 161: 111-123, 1994.
26. Xiao H, Hasegawa T, Miyaishi O, Ohkusu K and Isobe KI: Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21Waf/Cipl in p53-independent manner. Biochem Biophys Res Com 237: 457-460, 1997.
27. Hague A, Elder DJ, Hicks DJ and Paraskeva C: Apoptosis in colorectal tumor cell: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer 60: 400-406, 1995.
28. McBain JA, Eastman A, Novel CS and Mueller GC: Apoptotic death in adenocarcinoma cell lines by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol 53: 1357-1368, 1997.
29. Chang ST and Yung BY: Potentiation of sodium butyrate-induced apoptosis by vanadate in human promyelocytic leukemia cell line HL-60, Biochem Biophys Res Commun 221: 594-601, 1996.
30. Thomas GL, Henley A, Rowland TC, Sahai A, Griffin M and Birckbichler PJ: Enhanced apoptosis is transformed human lung fibroblasts after exposure to sodium butyrate. In Vitro Cell Dev Biol Animal 32: 505-513, 1996.
31. Conway RM, Madigan MC, Penfold PL and Billson FA: Induction of apoptosis by sodium butyrate in the human Y-79 retinoblastoma cell line. Oncol Res 7: 289-297, 1995.
32. Wang X-M, Wang X, Li J and Evers BM. Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. Ann Surg 227: 922-931, 1998.
33. Aden DP, Fogel A, Plotkin S, Damjanov I and Knowles BB: Controlled synthesis of HbsAg in a differentiated human liver carcinoma-derived cell line. Nature 282: 615-616, 1979.
34. Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499, 1980.
35. Albini A, Iwamoto Y, Kleinman HK, et al: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245, 1987.
36. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1987.
37. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR and Ozturk M: Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 1973-1977, 1990.
38. Hosono S, Lee CS, Chou MJ, et al: Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines. Oncogene 6: 237-243, 1991.
39. Yang Z-Y, Perkins ND, Ohno T, Nabel EG and Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1: 1052-1056, 1945.
40. Johnson DG, Richie ER and Conti CJ: The cell cycle and cancer. Cancer Bull 47: 480-485, 1995.
41. Waldman T, Kinzler KW and Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190, 1995.
42. Gorospe M, Shack S, Guyton KZ, Samid D and Holbrook NJ: Upregulation and functional role of p21waf1/cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ 7: 1609-1615, 1996.
43. Manfredi JJ, Tang H-Y and Waxman S: The cyclin-dependent kinase inhibitor p21 as a target for differentiation therapy. Mol Cell Differ 4: 33-45, 1996.
44. Tan P, Cady B, Wanner M, et al: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57: 1259-1263, 1997.
45. Yasui W, Kudo Y, Semba S, Yokozaki H and Tahara E: Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jap J Cancer Res 88: 625-629, 1997.
46. Fredersdorf S, Burns J, Milne AM, et al: High level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27 (kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380-6385, 1997.